| Transcript | Q3 FY25 earnings call transcript |
| 2026-08-05 | Press release | Charles River Laboratories Announces Second-Quarter 2026 Results |
| 2026-08-05 | Deck | Charles River Laboratories Q2 2026 Earnings Presentation |
| 2026-08-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-05 | 10-Q | Form 10-Q for the quarter ended Jun 27 |
| 2026-07-15 | Press release | Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call |
| 2026-07-13 | Press release | Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment |
| 2026-06-18 | Press release | Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise |
| 2026-06-02 | Deck | Charles River Laboratories at the William Blair 46th Annual Growth Stock Conference Presentation |
| 2026-06-01 | Press release | Charles River Laboratories to Present at William Blair and Jefferies Conferences |
| 2026-05-13 | Press release | Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions |
| 2026-05-11 | Press release | Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow |
| 2026-05-11 | 8-K | Form 8-K, Item 5.02 |
| 2026-05-07 | Press release | Charles River Laboratories Announces First-Quarter 2026 Results |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-07 | 10-Q | Form 10-Q for the quarter ended Mar 28 |
| 2026-04-30 | Press release | Charles River Launches Rat In Vitro Fertility Services Demonstrating Embryology Capabilities |
| 2026-04-21 | Press release | Charles River Highlights Effectiveness of VCGs in Toxicology |
| 2026-04-16 | Press release | Charles River Laboratories Schedules First-Quarter 2026 Earnings Release and Conference Call |
| 2026-04-09 | Press release | Charles River Advances Cardiovascular Health Awareness Through Support of the American Heart Association |
| 2026-03-31 | Proxy | Definitive proxy statement |
| 2026-03-26 | ESG report | 2025 ESG Data Table |
| 2026-03-19 | Document | 2026 NHP Board Report |
| 2026-03-02 | Press release | Charles River Laboratories to Present at TD Cowen and Barclays Conferences |
| 2026-02-25 | Press release | Charles River Laboratories Provides Update on Planned Divestitures |
| 2026-02-25 | 8-K | Form 8-K, Item 7.01 |
| 2026-02-19 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-18 | Press release | Charles River Laboratories Announces Executive Appointments |
| 2026-02-18 | Press release | Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance |
| 2026-02-18 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-18 | 8-K | Form 8-K, Item 5.02 |
| 2026-02-18 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-01-21 | Press release | Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call |
| 2026-01-21 | Press release | Charles River Enters Manufacturing Collaboration with Gazi University |
| 2026-01-13 | 8-K | Form 8-K, Item 2.02 results |
| 2026-01-12 | Press release | Charles River Laboratories Provides Business Updates |
| 2026-01-09 | 8-K | Form 8-K, Item 5.02 |
| 2026-01-08 | Press release | Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan |
| 2025-12-03 | 8-K | Form 8-K, Item 7.01 |
| 2025-11-17 | 8-K | Form 8-K, Item 8.01 |